GLSI
Greenwich LifeSciences, Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Sell
-40/100
Last price
15.97
▼ 0.94 (5.56%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
16.92
Prev close
16.91
Day high
17.06
Day low
15.40
Volume
113.53K
Market cap
$231.77M
P/E (TTM)
—
52W range
7.78 – 34.10
Day trading desk
Gap from prior close
+0.06%
Prior close 16.91
VWAP
16.04
-0.43% from price
Relative volume
1.53×
Unusually busy
Session range
10.78%
15.40 – 17.06
Position in range
34%
Mid range
ATR (14D)
1.53
9.61% of price
Prior day high
17.25
PDH
Prior day low
16.26
PDL
Bid / ask spread
—
Quote not published
Session volume
213.49K
Avg 139.47K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
-14.09%
-16.0%
1M
-1.00%
-2.2%
3M
-16.32%
-20.8%
6M
-29.85%
-48.0%
YTD
-24.85%
-39.1%
1Y
+44.73%
+28.3%
3Y
+78.62%
-3.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on GLSI open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
7.03M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jul 29, 26 | PATEL SNEHAL Chief Executive Officer |
BUY | 2.20K | $29.55K | Direct |
| Jul 27, 26 | PATEL SNEHAL Officer, Director and Beneficial Owner |
BUY | 1.50K | $20.43K | Direct |
| Jul 24, 26 | PATEL SNEHAL Chief Executive Officer |
BUY | 3.60K | $47.02K | Direct |
| Jan 13, 26 | PATEL SNEHAL Chief Executive Officer |
BUY | 1.80K | $53.69K | Direct |
| Jan 12, 26 | PATEL SNEHAL Chief Executive Officer |
BUY | 2.90K | $79.87K | Direct |
| Dec 31, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 4.30K | $91.85K | Direct |
| Dec 30, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 2.90K | $63.02K | Direct |
| Dec 18, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 4.10K | $51.74K | Direct |
| Nov 25, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 4.60K | $38.50K | Direct |
| Nov 7, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 10.60K | $89.36K | Direct |
| Oct 31, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 2.30K | $21.30K | Direct |
| Apr 25, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 3.60K | $35.57K | Direct |
| Apr 17, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 5.40K | $48.49K | Direct |
| Apr 7, 25 | PATEL SNEHAL Chief Executive Officer |
BUY | 3.60K | $32.76K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
PATEL SNEHAL |
Chief Executive Officer | 5.61M | Purchase |
THOMPSON JAYE L |
Officer | 264.15K | Purchase |
Fundamentals
Market cap$231.77M
Enterprise value$222.89M
Revenue (TTM)—
Gross profit—
EBITDA$-22.66M
Net income$-22.47M
EPS (TTM)$-1.43
Free cash flow$-3.34M
Total cash$8.88M
Total debt$0
Book value / share$0.21
Shares outstanding14.68M
Float7.65M
Short % of float21.31%
Dividend yield0.00%
Beta (5Y)1.46
Valuation & profitability ratios
Trailing P/E—
Forward P/E-19.26
PEG ratio—
Price / sales—
Price / book74.48
EV / revenue—
EV / EBITDA-9.84
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-986.32%
Return on assets-235.98%
Debt / equity—
Current ratio1.54
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $17.22M | $15.48M | $7.70M | $6.48M | +11.2% |
| Selling, general & admin | $2.23M | $2.16M | $1.63M | $1.56M | +3.3% |
| Total operating expense | $19.45M | $17.64M | $9.33M | $8.04M | +10.3% |
| Operating income | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -10.3% |
| Net interest income | $89.70K | $223.01K | $436.06K | $215.02K | -59.8% |
| Pre-tax income | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -11.2% |
| Net income | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -11.2% |
| Net income to common | -$19.36M | -$17.41M | -$8.89M | -$7.83M | -11.2% |
| Basic EPS | -1.43 | -1.34 | -0.69 | -0.61 | -6.7% |
| Diluted EPS | -1.43 | -1.34 | -0.69 | -0.61 | -6.7% |
| EBIT | -$19.45M | -$17.64M | -$9.33M | -$8.04M | -10.3% |
| EBITDA | -$19.45M | -$17.63M | -$9.32M | -$8.04M | -10.3% |
| Basic shares | 13.53M | 13.01M | 12.85M | 12.91M | +4.0% |
| Diluted shares | 13.53M | 13.01M | 12.85M | 12.91M | +4.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $6.18M | $4.09M | $6.99M | $13.47M | +51.0% |
| Cash & short-term investments | $6.18M | $4.09M | $6.99M | $13.47M | +51.0% |
| Total current assets | $6.18M | $4.09M | $6.99M | $13.47M | +51.0% |
| Goodwill & intangibles | $0 | $1.78K | $5.39K | $9.00K | -100.0% |
| Total assets | $6.18M | $4.09M | $6.99M | $13.48M | +50.9% |
| Total current liabilities | $5.82M | $3.19M | $294.41K | $262.90K | +82.9% |
| Total liabilities | $5.82M | $3.19M | $294.41K | $262.90K | +82.9% |
| Retained earnings | -$87.14M | -$67.78M | -$50.36M | -$41.47M | -28.6% |
| Shareholder equity | $353.22K | $908.63K | $6.70M | $13.21M | -61.1% |
| Working capital | $353.22K | $906.85K | $6.70M | $13.21M | -61.0% |
| Net tangible assets | $353.22K | $906.85K | $6.70M | $13.21M | -61.0% |
| Shares issued | 14.30M | 13.15M | 12.85M | 12.85M | +8.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$19.36M | -$17.41M | -$8.89M | -$7.83M | — | -11.2% |
| Depreciation & amortisation | $1.78K | $3.61K | $3.61K | $3.61K | — | -50.7% |
| Stock-based compensation | $6.80M | $7.25M | $2.38M | $1.74M | — | -6.2% |
| Change in working capital | $2.64M | $2.89M | $31.50K | -$122.27K | — | -8.7% |
| Operating cash flow | -$9.91M | -$7.27M | -$6.48M | -$6.20M | — | -36.4% |
| Share buybacks | — | — | $0 | -$7.54M | $0 | — |
| Financing cash flow | $12.00M | $4.37M | $0 | -$7.54M | — | +174.6% |
| Free cash flow | -$9.91M | -$7.27M | -$6.48M | -$6.20M | — | -36.4% |
| End cash position | $6.18M | $4.09M | $6.99M | $13.47M | — | +51.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $3.56M | $5.21M | $7.59M | $3.52M | $3.42M | — | -31.7% |
| Selling, general & admin | $462.93K | $518.19K | $355.19K | $653.07K | $352.84K | — | -10.7% |
| Total operating expense | $4.02M | $5.73M | $7.94M | $4.17M | $3.77M | — | -29.8% |
| Operating income | -$4.02M | -$5.73M | -$7.94M | -$4.17M | -$3.77M | — | +29.8% |
| Net interest income | $72.97K | $68.62K | $22.26K | $22.80K | $20.68K | — | +6.3% |
| Pre-tax income | -$3.95M | -$5.66M | -$7.92M | -$4.15M | -$3.75M | — | +30.2% |
| Net income | -$3.95M | -$5.66M | -$7.92M | -$4.15M | -$3.75M | — | +30.2% |
| Net income to common | -$3.95M | -$5.66M | -$7.92M | -$4.15M | -$3.75M | — | +30.2% |
| Basic EPS | -0.27 | -0.39 | — | -0.30 | -0.28 | -0.21 | +30.8% |
| Diluted EPS | -0.27 | -0.39 | — | -0.30 | -0.28 | -0.21 | +30.8% |
| EBIT | -$4.02M | -$5.73M | -$7.94M | -$4.17M | -$3.77M | — | +29.8% |
| EBITDA | -$4.02M | -$5.73M | -$7.94M | -$4.17M | -$3.77M | — | +29.8% |
| Basic shares | 14.62M | 14.57M | — | 13.64M | 13.37M | 13.17M | +0.4% |
| Diluted shares | 14.62M | 14.57M | — | 13.64M | 13.37M | 13.17M | +0.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | -15.5% |
| Cash & short-term investments | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | -15.5% |
| Total current assets | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | -15.5% |
| Goodwill & intangibles | — | — | $0 | — | — | — |
| Total assets | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | -15.5% |
| Total current liabilities | $5.76M | $5.24M | $5.82M | $1.62M | $1.69M | +10.0% |
| Total liabilities | $5.76M | $5.24M | $5.82M | $1.62M | $1.69M | +10.0% |
| Retained earnings | -$96.74M | -$92.79M | -$87.14M | -$77.59M | -$73.44M | -4.3% |
| Shareholder equity | $3.12M | $5.27M | $353.22K | $2.18M | $1.44M | -40.9% |
| Working capital | $3.12M | $5.27M | $353.22K | $2.18M | $1.44M | -40.9% |
| Net tangible assets | $3.12M | $5.27M | $353.22K | $2.18M | $1.44M | -40.9% |
| Shares issued | 14.68M | 14.67M | 14.30M | 13.79M | 13.47M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | -$3.95M | -$5.66M | -$7.92M | -$4.94M | -$3.75M | — | +30.2% |
| Depreciation & amortisation | — | $0 | $0 | $0 | $876 | $903 | — |
| Stock-based compensation | $1.48M | $1.54M | $2.17M | $1.54M | $1.54M | — | -3.8% |
| Change in working capital | $524.17K | -$589.58K | $2.58M | $726.61K | -$29.55K | — | +188.9% |
| Operating cash flow | -$1.94M | -$4.70M | -$3.17M | -$2.67M | -$2.23M | — | +58.8% |
| Financing cash flow | $310.66K | $9.03M | $5.55M | $3.35M | $2.61M | — | -96.6% |
| Free cash flow | -$1.94M | -$4.70M | -$3.17M | -$2.67M | -$2.23M | — | +58.8% |
| End cash position | $8.88M | $10.51M | $6.18M | $3.81M | $3.13M | — | -15.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.33 | -0.27 | +18.2% |
| Mar 2026 | -0.35 | -0.39 | -11.4% |
| Dec 2025 | -0.32 | -0.58 | -81.3% |
| Sep 2025 | -0.36 | -0.30 | +16.7% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.34 | 2 | $0 | 0.0% |
| Next quarter | -0.35 | 2 | $0 | 0.0% |
| Current year | -1.39 | 2 | $0 | 0.0% |
| Next year | -1.17 | 1 | $0 | 0.0% |
Analyst targets & ownership
Mean target$57.00
High target$69.00
Low target$45.00
Implied upside256.92%
Analyst count2
ConsensusNONE
Strong buy / Buy0 / 2
Hold0
Sell / Strong sell0 / 0
Held by insiders47.91%
Held by institutions12.25%
Institutions holding94
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
17.59
-9.20% from price
SMA 20
17.23
-8.37% from price
SMA 50
16.33
-3.29% from price
SMA 100
19.18
-16.72% from price
SMA 200
21.96
-28.09% from price
EMA 12
17.28
-7.58% from price
EMA 26
17.15
-6.88% from price
EMA 50
17.32
-7.79% from price
RSI (14)
41.8
Neutral
MACD (12,26,9)
0.13
Hist -0.22
ATR (14)
1.53
9.72% of price
Realised vol 30D
90.2%
Annualised
Bollinger upper
19.96
20, 2σ
Bollinger lower
14.50
20, 2σ
50 / 200 cross
Death
16.33 vs 21.96
Trend bias
Below 200
-28.09%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
3.00
More volatile than market
Correlation to SPY
0.38
Loosely linked
Realised vol 30D
90.2%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-61.9%
Peak to trough
Max drawdown 5Y
-81.9%
Peak to trough
ATR 14
1.53
9.72% of price
Beta (reported)
1.46
5Y monthly, from filing
Short interest
Shares short
1.63M
Prior 1.59M
Change vs prior
+2.3%
Shorts adding
% of float
21.31%
Heavily shorted
% of shares out
11.11%
Against total outstanding
Days to cover
14.0
Crowded exit
Float
7.65M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 21, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Dec 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 11, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 23, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 28, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 20, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Apr 10, 23 | HC Wainwright & Co. | MAINTAINED | — | Buy |
| Sep 1, 21 | HC Wainwright & Co. | INITIATED | — | Buy |
| Jan 27, 21 | Aegis Capital | INITIATED | — | Buy |
| Jan 26, 21 | Aegis Capital | INITIATED | — | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio—
Ex-dividend date—
Next pay date—
Last split—
Split date—
SEC filings
Periodic Financial Reports
10-Q · 2026-08-11
Periodic Financial Reports
10-Q · 2026-06-04
Periodic Financial Reports
10-K · 2026-06-01
Periodic Financial Reports
NT 10-K · 2026-03-31
Corporate Changes & Voting Matters
8-K · 2025-12-18
Periodic Financial Reports
10-Q · 2025-11-14
Proxy Statements
DEF 14A · 2025-11-03
Periodic Financial Reports
10-Q · 2025-08-14
Headlines
3 Clinical-Stage Cancer Stocks With Pristine Balance Sheets
Simply Wall St. · 21d ago
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027
GlobeNewswire · 58d ago
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom
GlobeNewswire · 77d ago
Greenwich LifeSciences Provides Clinical Updates on FLAMINGO-01
GlobeNewswire · 79d ago
Greenwich LifeSciences Says EU Regulator Approves Combination of HLA Patients in Phase 3 Trial
MT Newswires · 83d ago
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01
GlobeNewswire · 83d ago
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday
MT Newswires · 90d ago
Sector Update: Healthcare
MT Newswires · 90d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.